Trial · NCT01589302
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 158
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye Infection | Infections and infestations | Treatment (Ibrutinib) | 8 | 152 | 9 |
| other | Infections and Infestations | Infections and infestations | Treatment (Ibrutinib) | 32 | 152 | 41 |
| other | Lung Infection | Infections and infestations | Treatment (Ibrutinib) | 30 | 152 | 43 |
| other | Nail Infection | Infections and infestations | Treatment (Ibrutinib) | 9 | 152 | 9 |
| other | Paronychia | Infections and infestations | Treatment (Ibrutinib) | 11 | 152 | 18 |
| other | Sinusitis | Infections and infestations | Treatment (Ibrutinib) | 49 | 152 | 68 |
| other | Skin Infection | Infections and infestations | Treatment (Ibrutinib) | 35 | 152 | 43 |
| other | Upper Respiratory Infection | Infections and infestations | Treatment (Ibrutinib) | 72 | 152 | 129 |
| other | Urinary Tract Infection | Infections and infestations | Treatment (Ibrutinib) | 30 | 152 | 52 |
| other | Bruising | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 70 | 152 | 93 |
| other | Fall | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 20 | 152 | 32 |
| other | Injury, Poisoning and procedural complications | Injury, poisoning and procedural complications | Treatment (Ibrutinib) | 7 | 152 | 7 |
| other | Lymphocyte count decreased | Investigations | Treatment (Ibrutinib) | 25 | 152 | 36 |
| other | Lymphocyte count increased | Investigations | Treatment (Ibrutinib) | 70 | 152 | 87 |
| other | Neutrophil count decreased | Investigations | Treatment (Ibrutinib) | 80 | 152 | 166 |
| other | Platelet count decreased | Investigations | Treatment (Ibrutinib) | 44 | 152 | 52 |
| other | Weight gain | Investigations | Treatment (Ibrutinib) | 65 | 152 | 75 |
| other | Weight loss | Investigations | Treatment (Ibrutinib) | 39 | 152 | 53 |
| other | White Blood cell decreased | Investigations | Treatment (Ibrutinib) | 27 | 152 | 38 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 39 | 152 | 39 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/events?page=3